Enhertu Trastuzumab Deruxtecan injection is used to treat unresectable (not able to be removed with surgery) and metastatic HER2-positive breast cancer that has been treated with two or more anti-HER2 therapies.

Enhertu (Trastuzumab Deruxtecan)) approved in the US for HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens.

  • ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

  • This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

    Enhertu Trastuzumab Deruxtecan injection suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

    IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

    For procurement cost of Enhertu (Trastuzumab Deruxtecan) injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Enhertu (Trastuzumab Deruxtecan) injection medicine cost price in India.

    The order for Enhertu Trastuzumab Deruxtecan injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

    Trastuzumab deruxtecan also known as fam-trastuzumab deruxtecan and sold under the brand name Enhertu, is a medication used for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

  • Trastuzumab deruxtecan is an antibody-drug conjugate that includes a human epidermal growth factor receptor 2 (HER2)-directed antibody trastuzumab and a topoisomerase I inhibitor conjugate deruxtecan (a derivative of exatecan).It was approved for use in the United States in December 2019.
  • Enhertu (Trastuzumab Deruxtecan) injection for oral administration Initial U.S. Approval: 2009

    Generic Name: Trastuzumab Deruxtecan

    For injection: 100 mg lyophilized powder in a single-dose vial

    Enhertu (Trastuzumab Deruxtecan) injection

    Enhertu (Trastuzumab Deruxtecan) injection injection, for oral use is available.

    Get In Touch

    Enhertu (Trastuzumab Deruxtecan) injection suppliers in India

    IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand pemnat (Pemetrexed) Injection on prescription and Import License in Patient's Name only.

    For overseas patients, pemnat (Pemetrexed) Injection can be made available in Send your enquiry to find pemnat (Pemetrexed) Injection in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

    News / Update for Enhertu (Trastuzumab Deruxtecan).

    For Enhertu (Trastuzumab Deruxtecan) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

    Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. For More Details

    FDA Approves Generic Trastuzumab Deruxtecan injection For More Details

    Channel Partner In India

    Delhi Office

    60/4, T&T House. Yusuf Sarai,
    New Delhi:110016

    Bangalore Office

    #308, Raheja Chambers, 12,
    Museum Road, Bangalore 560 001

    Kolkata Office

    1/A R.G Kar Road, Shayambazar,
    Kolkata 700004

    Lucknow Office

    203-A, 2nd Floor, Tower -11, Felix
    Square, IBB-2, Sushant Golf city, Lucknow 226030